Logo

People in the News: Luis Gutierrez, Glenn Hoke, Valerie Palmieri

Oct 31, 2014
Premium

Theranostics Health has appointed Luis Gutierrez president and CEO. Former CEO Glenn Hoke will remain with the company as executive vice president and COO.

Gutierrez was previously executive vice president and COO of Aptiv Solutions. Before that he was president of Covance's commercialization services division. He has also held management roles at Merck and MedAssurant.

Vermillion has appointed Valerie Palmieri to the newly created position of COO.

Previously, Palmieri was president of Momentum Consulting, through which she has served as a strategic advisor to Vermillion for the past six months, helping the company launch Aspira Labs, its CLIA certified facility. Prior to that she was CEO of two healthcare start-ups, as well as national vice president of anatomic pathology operations at LabCorp/Dianon.

Filed under

Proteomics & Protein Research
proteomics
Vermillion
Theranostics Health
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.